Bladder Cancer Coverage from Every Angle

AUA 2021: Antibody Levels as Predictors of Response to Immunotherapy in Bladder Cancer

By: Vanessa A. Carter, BS
Posted: Friday, October 1, 2021

Anirban P. Mitra, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues conducted a secondary analysis of a phase III trial that assessed the predictive value of antiadenoviral antibody levels on therapeutic response in patients with non–muscle-invasive bladder cancer receiving nadofaragene firadenovec—a recombinant, adenoviral vector–based intravesical therapy. During the 2021 American Urological Association (AUA) Annual Meeting (Abstract PD09-02), these researchers revealed that a combination of antibody fold-change levels and titers may, in fact, predict therapeutic response.

This study focused on 157 patients with high-grade, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer who were administered nadofaragene firadenovec therapy. Participants received 75 mL of treatment intravesically once every 3 months for up to four doses. Serum antibody levels were obtained 1 to 24 hours before treatment and every 3 months until 1 year or study withdrawal.

The rate of complete response was 60% at the 3-month follow-up, and this rate was maintained in 51% of patients during the 12-month follow-up. A total of 91 participants had evaluable antibody levels, and 57 individuals had carcinoma in situ. At the 12-month mark, 52% of patients were high-grade recurrence-free.

Antibody titers while on therapy were either at or above baseline levels, with 89% of responders and 59% of nonresponders exhibiting titers higher than 800 U/mL (P = .001). Additionally, there was an on-treatment antibody fold-change of more than eight from baseline in 51% of responders and 27% of nonresponders (P = .02). Furthermore, a combination of elevated antibody titers and fold-change levels were observed in 47% and 18% of responders and nonresponders, respectively (P = .004).

Disclosure: No disclosure information was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.